Mga Batayang Estadistika
| LEI | 549300TNBRYXYEAI2956 |
| CIK | 1551986 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to 9 Meters Biopharma Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 7, 2024 |
US6544052086 / 9 Meters Biopharma Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. Passive Investment SC 13G/A 1 p24-0603sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* 9 Meters Biopharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 654405208 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizati |
|
| July 18, 2023 |
SECOND FORBEARANCE AND AMENDMENT AGREEMENT Exhibit 10.1 EXECUTION SECOND FORBEARANCE AND AMENDMENT AGREEMENT THIS SECOND FORBEARANCE AND AMENDMENT AGREEMENT (this “Agreement”), effective as of June 29, 2023, is by and among HIGH TRAIL SPECIAL SITUATIONS LLC, a Delaware limited liability company (in its capacity as holder, secured party or collateral agent, as applicable, “Purchaser”), 9 Meters Biopharma, Inc., a Delaware corporation (“Issu |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizati |
|
| May 30, 2023 |
Press Release 9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizatio |
|
| May 30, 2023 |
SEPARATION AGREEMENT AND RELEASE SEPARATION AGREEMENT AND RELEASE This SEPARATION AGREEMENT AND RELEASE (the “Agreement”) is hereby made and entered into this 26th day of May, 2023 by and between 9 Meters Biopharma, Inc. |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizatio |
|
| May 19, 2023 |
AMENDMENT NO. 1 TO FORBEARANCE AGREEMENT EX-10.1 AMENDMENT NO. 1 TO FORBEARANCE AGREEMENT THIS AMENDMENT NO. 1 TO FORBEARANCE AGREEMENT (this “Amendment”) is entered into as of May 18, 2023 by and among HIGH TRAIL SPECIAL SITUATIONS LLC, a Delaware limited liability company (in its capacity as holder, secured party or collateral agent, as applicable, “Purchaser”), 9 Meters Biopharma, Inc., a Delaware corporation (“Issuer”), and Naia Rare |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 18, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizatio |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: þ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| May 15, 2023 |
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023 Press Release 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023 RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37797 9 METERS B |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizatio |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-3 |
|
| April 27, 2023 |
Forbearance Agreement, dated April 26, 2023. FORBEARANCE AGREEMENT THIS FORBEARANCE AGREEMENT (this “Agreement”) dated as of April 26, 2023, is by and among HIGH TRAIL SPECIAL SITUATIONS LLC, a Delaware limited liability company (in its capacity as holder, secured party or collateral agent, as applicable, “Purchaser”), 9 Meters Biopharma, Inc. |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| April 5, 2023 |
Exhibit 99.1 PRESS RELEASE 9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding its GIP Antagonist NM-136 for Obesity RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food an |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 5, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizati |
|
| March 28, 2023 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The authorized capital stock of 9 Meters Biopharma, Inc. consists of 550,000,000 shares of common stock, $0.0001 par value per share (“Common Stock”), and 10,000,000 shares of preferred stock, par value $0.0001 per share (“Preferred Stock”). We have one class of securitie |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37797 9 METERS BIOPHA |
|
| March 28, 2023 |
Form of Retention Bonus Agreement. March 28, 2023 VIA EMAIL [Full Name] Re: Retention Bonus Dear [Name]: In consideration for your continued employment with 9 Meters Biopharma, Inc. |
|
| March 28, 2023 |
Press Release 9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022 RALEIGH, NC / ACCESSWIRE / March 28, 2023 / 9 Meters Biopharma, Inc. |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| March 15, 2023 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT 9 METERS BIOPHARMA, INC. Warrant Shares: [] Initial Exercise Date: March 15, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| March 15, 2023 |
Press Release 9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules RALEIGH, NC / ACCESSWIRE / March 14, 2023 / 9 Meters Biopharma, Inc. |
|
| March 15, 2023 |
Press Release 9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules RALEIGH, NC / ACCESSWIRE / March 15, 2023 / 9 Meters Biopharma, Inc. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| March 15, 2023 |
Form of Placement Agent Warrant. PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT 9 METERS BIOPHARMA, INC. Warrant Shares: Initial Exercise Date: March 15, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d |
|
| March 15, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration Number 333-249268 Prospectus supplement (To prospectus dated October 9, 2020) 1,300,000 Shares of Common Stock Warrants to Purchase up to 6,250,000 Shares of Common Stock Pre-Funded Warrants to purchase up to 1,825,000 Shares of Common Stock Placement Agent Warrants to Purchase up to 187,500 Shares of Common Stock (and shares of Common Stock underlying the Warrants, Pre-Funded Warrants and Placement Agent Warrants) Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 1,300,000 shares of our common stock, par value $0. |
|
| March 15, 2023 |
COMMON STOCK PURCHASE WARRANT 9 METERS BIOPHARMA, INC. Warrant Shares: [] Initial Exercise Date: March 15, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial E |
|
| March 15, 2023 |
Form of Securities Purchase Agreement. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 13, 2023, between 9 Meters Biopharma, Inc. |
|
| March 13, 2023 |
ex-991corporatepresentat Pioneering Novel Treatments C L IN IC AL STAG E C O M PANY P IO NE E R ING NOVE L T R E AT M E NT S FO R PE O PL E W IT H R AR E O R D E B IL ITAT ING D IG E ST IVE D IS E AS E S with a one-tract mind This presentation includes forward-looking statements based upon 9 Meters' current expectations. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| February 9, 2023 |
SC 13G/A 1 p23-0712sc13ga.htm 9 METERS BIOPHARMA, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* 9 Meters Biopharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 654405208 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statemen |
|
| January 13, 2023 |
First Amendment to the Amended and Restated Senior Secured Convertible Note Due 2025. FIRST AMENDMENT TO AMENDED AND RESTATED SENIOR SECURED CONVERTIBLE NOTE DUE 2025 This FIRST AMENDMENT TO AMENDED AND RESTATED SENIOR SECURED CONVERTIBLE NOTE DUE 2025 (this “Amendment”) is made and entered into as of January 12, 2023, by and between 9 Meters Biopharma, Inc. |
|
| January 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 12, 2023 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| November 29, 2022 |
ex-992corporatepresentat 1 Pioneering Novel Treatments with a one-tract mind CLINICAL STAGE COMPANY P IONEERING NOVEL TREATMENTS FOR PEOPLE WITH RARE OR DEBIL ITAT ING DIGEST IVE D ISEASES Forward-looking statements This presentation includes forward-looking statements based upon 9 Meters' current expectations. |
|
| November 29, 2022 |
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome Press Release 9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome •Study design incorporates two primary endpoints to evaluate the efficacy of vurolenatide in short bowel syndrome with or without parenteral support dependence •Study design allows for the assessment of the entirety of the short bowel syndrome patient population •US IRB approval secured; study to include up to 50 sites in North America and Europe and remains on track with study initiation as early as end-of-year RALEIGH, NC / ACCESSWIRE / November 29, 2022/ 9 Meters Biopharma, Inc. |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 29, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organi |
|
| November 8, 2022 |
Amended and Restated Certificate of Incorporation of the Company, as amended. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INNOVATE BIOPHARMACEUTICALS, INC. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| November 8, 2022 |
9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022 9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022 •Positive final results from the vurolenatide Phase 2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimen •Clinical plans and activities are underway including site and patient recruitment to facilitate Phase 3 study initiation upon protocol finalization with FDA this quarter RALEIGH, NC / ACCESSWIRE / November 8, 2022 / 9 Meters Biopharma, Inc. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37797 9 METE |
|
| November 8, 2022 |
Form of Amended and Restated Senior Secured Convertible Note. Exhibit 10.1 9 Meters Biopharma, Inc. Amended and Restated Senior Secured Convertible Note due 2025 THE ISSUANCE AND SALE OF NEITHER THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES THAT MAY BE ISSUABLE PURSUANT TO THIS NOTE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. UNTIL THE DATE THAT IS ONE (1) |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 21, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| October 17, 2022 |
EX-3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED OF 9 METERS BIOPHARMA, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) 9 Meters Biopharma, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follow |
|
| October 17, 2022 |
9 Meters Biopharma Announces 1-for-20 Reverse Stock Split Press Release 9 Meters Biopharma Announces 1-for-20 Reverse Stock Split RALEIGH, NC / ACCESSWIRE / October 17, 2022 / 9 Meters Biopharma, Inc. |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 3, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiza |
|
| October 6, 2022 |
Exhibit 10.1 LEASE AGREEMENT between CRABTREE TERRACE HOLDINGS LLC ("LANDLORD") and 9 METERS BIOPHARMA, INC. ("TENANT") TABLE OF CONTENTS ARTICLE I BASIC LEASE TERMS Section 1.01 Landlord................................................................................................................... Section 1.02 Tenant ............................................................................. |
|
| September 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organ |
|
| September 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| September 26, 2022 |
1 Pioneering Novel Treatments with a one-tract mind CLINICAL STAGE COMPANY P IONEERING NOVEL TREATMENTS FOR PEOPLE WITH RARE OR DEBIL ITAT ING DIGEST IVE D ISEASES Forward-looking statements This presentation includes forward-looking statements based upon 9 Meters' current expectations. |
|
| September 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organ |
|
| September 26, 2022 |
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome ?Vurolenatide 50 mg every two weeks (Q2W) dosing arm demonstrated a 30% reduction over six weeks in the primary endpoint of the Phase 2 study, mean reduction in total stool output (TSO), compared with a 32% increase for placebo ? for |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 15, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiza |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37797 9 METERS BI |
|
| August 15, 2022 |
9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022 EX-99.1 2 ex-991pressrelease81522.htm EX-99.1 9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022 •Positive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announced •Vurolenatide End-of-Phase 2 meeting with FDA on track for 3Q •Cash balance as of June 30, 2022 of $29.5 million; additional $20 million from previou |
|
| August 15, 2022 |
Exclusive License Agreement between 9 Meters Biopharma, Inc. and EBRIS srl. CONFIDENTIAL PORTIONS OF THIS EXCLUSIVE LICENSE AGREEMENT HAVE BEEN OMITTED PURSUANT TO REGULATION S-K ITEM 601(a)(5) OR 601(b)(10)(iv) OF THE SECURITIES ACT OF 1933, AS AMENDED. |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| August 4, 2022 |
9 Meters Biopharma, Inc. 144,622,855 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-266377 PROSPECTUS 9 Meters Biopharma, Inc. 144,622,855 Shares of Common Stock This prospectus relates to the possible resale of up to 144,622,855 shares of our common stock, $0.0001 par value per share, from time to time in one or more offerings by the selling stockholder named herein and any additional selling stockholders who will be identifi |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| August 2, 2022 |
9 METERS BIOPHARMA, INC. 8480 Honeycutt Road, Suite 120 Raleigh, NC 27615 9 METERS BIOPHARMA, INC. 8480 Honeycutt Road, Suite 120 Raleigh, NC 27615 August 2, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: 9 Meters Biopharma, Inc. Registration Statement on Form S-3 Filed July 28, 2022 File No. 333-266377 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, |
|
| July 28, 2022 |
As filed with the Securities and Exchange Commission on July 28, 2022 As filed with the Securities and Exchange Commission on July 28, 2022 Registration Statement No. |
|
| July 28, 2022 |
Calculation of Registration Fee EX-FILING FEES 2 ex-107sx3filingfeetablejul.htm EX-FILING FEES Calculation of Filing Fee Table Form S-3 (Form Type) 9 Meters Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount To Be Registered (1) Proposed Maximum Offering Price Per Share (2) Ma |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* 9 Meters Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45782F105 (CUSIP Number) OrbiMed Israel BioFund GP Limited Partnership OrbiMed Israel GP Ltd. Erez Chimovits 89 Medinat HaYehudim St. Build |
|
| July 1, 2022 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. |
|
| June 30, 2022 |
Exhibit 99.1 9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome - Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel Syndrome RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitat |
|
| June 30, 2022 |
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome ?Phase 2 VIBRANT study identifies a dose and dosing interval with >25% improvement in the primary endpoint of 24-hour mean total stool output reduction over 6 weeks ?Vurolenatide was generally well tolerated with no adverse events leading to early study withdrawal ?End-of-Phase 2 meeting with FDA scheduled for mid-third quarter ?Phase 3 study for vurolenatide could begin as early as fourth quarter 2022 pending outcome of end-of-Phase 2 meeting; Study planning and logistics well underway RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. |
|
| June 30, 2022 |
Form of Senior Secured Convertible Note. Exhibit 10.2 9 Meters Biopharma, Inc. Senior Secured Convertible Note due 2025 THE ISSUANCE AND SALE OF NEITHER THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES THAT MAY BE ISSUABLE PURSUANT TO THIS NOTE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR APPLICABLE STATE SECURITIES LAWS. UNTIL THE DATE THAT IS ONE (1) YEAR AFTER THE ISSUE |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizati |
|
| June 30, 2022 |
Pioneering Novel Treatments with a one-tract mind FOCUSED ON RARE AND UNMET NEEDS IN DIGESTIVE DISEASES AND UNIQUE GI B IOLOGY June 28 , 2022 forward-looking statements This presentation includes forward-looking statements based upon the Company's current expectations. |
|
| June 30, 2022 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of June [ l ], 2022, is by and among 9 Meters Biopharma, Inc., a Delaware corporation with offices located at 8480 Honeycutt Road, Suite 120, Raleigh, North Carolina 27615 (the ?Company?), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a ?Buyer? and c |
|
| June 30, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizati |
|
| June 22, 2022 |
Form of 9 Meters Biopharma, Inc. Notice of Stock Option Grant and Award Agreement. EX-10.2 3 ex-102formofstockoptiongra.htm EX-10.2 9 METERS BIOPHARMA, INC. 2022 STOCK INCENTIVE PLAN NOTICE OF STOCK OPTION GRANT Optionee/Participant: You have been granted an option to purchase shares of the Common Stock of 9 Meters Biopharma, Inc. (the “Company”) as follows, subject to the terms of the 9 Meters Biopharma, Inc. 2022 Stock Incentive Plan (the “Plan”) and the attached Stock Option |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 22, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizati |
|
| June 22, 2022 |
As filed with the Securities and Exchange Commission on June 22, 2022 Registration No. |
|
| June 22, 2022 |
9 Meters Biopharma, Inc. 2022 Stock Incentive Plan. 9 METERS BIOPHARMA, INC. 2022 STOCK INCENTIVE PLAN 2022 Stock Incentive Plan Approved by the Board and Stockholders on May 4, 2022 and June 22, 2022, respectively 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel to serve as Employees, Directors or Consultants; to provide additional incentives to Employees, Directors and Consultants to contri |
|
| June 22, 2022 |
Calculation of Filing Fee Table Form S-8 (Form Type) 9 Meters Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount To Be Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par va |
|
| June 21, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 of 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizati |
|
| June 21, 2022 |
Press Release 9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation ?Additional analyses to determine if a subgroup of patients and/or symptoms may have been responsive to treatment ?Company remains on track to deliver vurolenatide Phase 2 short bowel syndrome results by end of month RALEIGH, NC / ACCESSWIRE / June 21, 2022 / 9 Meters Biopharma, Inc. |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37797 9 METERS B |
|
| May 16, 2022 |
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022 PRESS RELEASE 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022 ?On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in June ?Cash balance as of March 31, 2022, of $37. |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizatio |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 13, 2022 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 11, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| March 23, 2022 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?) is entered into effective as of July 12, 2021 (the ?Amendment Effective Date?), by and between 9 Meters Biopharma, Inc. |
|
| March 23, 2022 |
Pioneering Novel Treatments with a one-tract mind FOCUSED ON RARE AND UNMET NEEDS IN DIGESTIVE DISEASES AND UNIQUE GI B IOLOGY forward-looking statements This presentation includes forward-looking statements based upon the Company's current expectations. |
|
| March 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) 9 Meters Biopharma, Inc. |
|
| March 23, 2022 |
As filed with the Securities and Exchange Commission on March 23, 2022 Registration No. |
|
| March 23, 2022 |
PRESS RELEASE 9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021 ?Phase 2 topline vurolenatide data for short bowel syndrome anticipated in Q2 2022 ?Phase 3 larazotide interim analysis for celiac disease anticipated in early June 2022 ?Executive team strengthened with appointment of highly experienced professionals, including Chief Financial Officer, Chief Commercial Officer, and SVP of Investor Relations & Corporate Communications ?Year-ending cash of $47. |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37797 9 METERS BIOPHA |
|
| March 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| February 28, 2022 |
PRESS RELEASE 9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease RALEIGH, NC / ACCESSWIRE / February 28, 2021 / 9 Meters Biopharma, Inc. |
|
| February 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organi |
|
| February 11, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 8, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| February 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* 9 Meters Biopharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 654405109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs |
|
| January 24, 2022 |
PRESS RELEASE 9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors RALEIGH, NC / ACCESSWIRE / JANUARY 24, 2022 / 9 Meters Biopharma, Inc. |
|
| January 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 24, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| January 18, 2022 |
PRESS RELEASE 9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experience RALEIGH, NC / ACCESSWIRE / January 18, 2021 / 9 Meters Biopharma, Inc. |
|
| January 18, 2022 |
Employment Agreement between 9 Meters Biopharma, Inc. and Bethany Sensenig. Exhibit 10.1 November 30, 2021 Bethany L. Sensenig 35 Ryan Farm Rd Windham, NH 03087 Dear Bethany, On behalf of 9 Meters Biopharma, Inc. (the ?Company?), I am very pleased to extend an offer of employment to you. We hope that you will accept this offer and look forward to having a mutually successful relationship with you. The purpose of this letter is to summarize the terms of your employment wit |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 14, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| January 18, 2022 |
Exhibit 10.2 SEPARATION AND CONSULTING AGREEMENT This SEPARATION AND CONSULTING AGREEMENT (the ?Agreement?) is hereby made and entered into this 14th day of January, 2022, by and between 9 Meters Biopharma, Inc. (f/k/a Innovate Biopharmaceuticals, Inc.), a Delaware corporation (the ?Company?), and the undersigned employee, referred to in this Agreement as ?you.? WHEREAS, you and the Company are pa |
|
| January 3, 2022 |
PRESS RELEASE 9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. |
|
| January 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2022 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiza |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37797 9 METE |
|
| November 15, 2021 |
PRESS RELEASE 9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021 - Phase 2 vurolenatide VIBRANT study enrollment anticipated to be completed before year-end; topline results for short bowel syndrome expected in Q1 2022 ? - Larazotide Phase 3 for celiac disease interim analysis expected in Q2 2022 ? - Appointed Samantha Ventimiglia of Vertex to the Board of Directors - - Quarter ending cash of $53. |
|
| November 15, 2021 |
Pioneering Novel Treatments with a one-tract mind FOCUSED ON RARE AND UNMET NEEDS IN DIGESTIVE DISEASES AND UNIQUE GI BIOLOGY forward-looking statements This presentation includes forward-looking statements based upon the Company's current expectations. |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organi |
|
| November 15, 2021 |
Asset Purchase Agreement between 9 Meters Biopharma, Inc. and Lobesity, LLC, dated July 19, 2021. CONFIDENTIAL PORTIONS OF THIS ASSET PURCHASE AGREEMENT HAVE BEEN OMITTED PURSUANT TO REGULATION S-K ITEM 601(b)(2) OF THE SECURITIES ACT OF 1933, AS AMENDED. |
|
| November 10, 2021 |
EX-99.1 2 ex-991pressrelease111021.htm EX-99.1 PRESS RELEASE 9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator -Collaboration builds upon previous positive preclinical data warranting further investigation of NM-102, a potential novel therapy to enhance immune checkpoint inhibitor effect- -IND-enabling pathway for NM-102 und |
|
| November 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organi |
|
| October 26, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| October 26, 2021 |
PRESS RELEASE 9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting ?Vurolenatide?s half-life is consistent with twice-monthly dosing ? ? Top-line results from the ongoing Phase 2 VIBRANT trial on track to be reported before year |
|
| October 4, 2021 |
9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors PRESS RELEASE 9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors RALEIGH, NC / ACCESSWIRE / October 4, 2021 / 9 Meters Biopharma, Inc. (NASDAQ: NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Samantha Ventimiglia to its Board of Dire |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 1, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiza |
|
| August 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 16, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiza |
|
| August 16, 2021 |
PRESS RELEASE 9 Meters Biopharma, Inc. Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Resulting from COVID-19 -Study May Proceed Letter Received from FDA Under Investigator IND- -EBRIS plans to initiate Phase 2a trial in MIS-C in Q4 2021 at Massachusetts General Hospital for Children- |
|
| August 12, 2021 |
Amended and Restated Certificate of Incorporation of 9 Meters Biopharma, Inc., as amended. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INNOVATE BIOPHARMACEUTICALS, INC. |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiza |
|
| August 12, 2021 |
PRESS RELEASE 9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021 - Initiated Phase 2 VIBRANT study of vurolenatide for short bowel syndrome (SBS) in Q2; total stool output (TSO) is primary endpoint following FDA guidance - - Expect Phase 2 data from VIBRANT in Q4 2021 - - Acquired humanized anti-GIP (glucose-dependent insulinotropic polypeptide) monoclonal antibody from Lobesity - Current capital is sufficient to fund operations into 2023 - Raleigh, NC, August 12, 2021 ? 9 Meters Biopharma, Inc. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37797 9 METERS BI |
|
| July 26, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizati |
|
| July 26, 2021 |
Pioneering Novel Treatments with a one-tract mind FOCUSED ON RARE AND UNMET NEEDS IN DIGESTIVE DISEASES AND UNIQUE GI BIOLOGY forward-looking statements This includes forward-looking statements based upon the Company's current expectations. |
|
| July 19, 2021 |
9 Meters ? Lobesity Asset Purchase Acquisition July 19, 2021 Forward Looking Statements This presentation includes forward-looking statements based upon the Company's current expectations. |
|
| July 19, 2021 |
PRESS RELEASE 9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity ?Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide (GIP) ? ?First planned indication is Prader-Willi Syndrome- ?IND-enabling studies ongoing with first-in-human studies anticipated in 2023 ? ?Transaction do |
|
| July 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizati |
|
| June 28, 2021 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. |
|
| June 28, 2021 |
9 Meters Added to Russell 2000® and 3000® Indexes PRESS RELEASE 9 Meters Added to Russell 2000? and 3000? Indexes RALEIGH, NC / June 28, 2021 / 9 Meters Biopharma, Inc. |
|
| June 28, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizati |
|
| June 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* 9 Meters Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45782F105 (CUSIP Number) OrbiMed Israel BioFund GP Limited Partnership OrbiMed Israel GP Ltd. Nissim Darvish 89 Medinat HaYehudim St. Build |
|
| June 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 22, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizati |
|
| June 23, 2021 |
Amendment to the 9 Meters Biopharma, Inc. Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED OF 9 METERS BIOPHARMA, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) 9 Meters Biopharma, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify as f |
|
| June 14, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizati |
|
| June 14, 2021 |
PRESS RELEASE 9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome ?Initiating the largest Phase 2 placebo-controlled trial in short bowel syndrome - ?Topline results of the multicenter VIBRANT study anticipated in Q4 2021 - RALEIGH, NC / June 14, 2021 / 9 Meters Biopharma, Inc. |
|
| May 26, 2021 |
PRESS RELEASE 9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children (MIS-C) resulting from COVID-19 Infection - Larazotide supplied to study authors under an FDA-approved Expanded Access Program - - Treatment showed a dramatic drop in inflammatory mediators leading to cl |
|
| May 26, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizatio |
|
| May 17, 2021 |
Exhibit 99.1 9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome RALEIGH, NC / ACCESSWIRE / May 17, 2021 / 9 Meters Biopharma, Inc. (NASDAQ: NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the United States Adopted Nam |
|
| May 17, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizatio |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37797 9 METERS B |
|
| May 13, 2021 |
EX-99.1 2 ex-991pressrelease51321.htm EX-99.1 PRESS RELEASE 9 Meters Biopharma Provides Business Update and Reports Financial Results for the First Quarter 2021 - Company closed a $31.5M equity offering in April 2021; provides cash runway into 2023 - Plan to initiate Phase 2 trial with NM-002 in SBS with total stool output as the primary endpoint in Q2 following FDA guidance - Announced a collabor |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizatio |
|
| May 12, 2021 |
DEF 14A 1 def14a2021.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Onl |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| April 21, 2021 |
9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit PRESS RELEASE 9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit Raleigh, NC, April 21, 2021 ? 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that management will participate in the 7th Annual Truist Securities Life Sciences Summit and invites investors to participat |
|
| April 19, 2021 |
EX-99.1 2 ex-991pressrelease41921.htm EX-99.1 PRESS RELEASE 9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters’ Program in Short Bowel Syndrome RALEIGH, NC / ACCESSWIRE / April 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company w |
|
| April 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 19, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| April 12, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 12, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| April 12, 2021 |
PRESS RELEASE 9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters? Phase 3 CeDLara Study RALEIGH, NC / ACCESSWIRE / April 12, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will collaborate with the Celiac Disease |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* 9 Meters Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45782F105 (CUSIP Number) OrbiMed Israel BioFund GP Limited Partnership OrbiMed Israel GP Ltd. Erez Chimovits 89 Medinat HaYehudim St. Build |
|
| April 7, 2021 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. |
|
| April 5, 2021 |
9 Meters Biopharma Prices Public Offering of Common Stock PRESS RELEASE 9 Meters Biopharma Prices Public Offering of Common Stock RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. |
|
| April 5, 2021 |
9 Meters Biopharma Announces Proposed Public Offering of Common Stock PRESS RELEASE 9 Meters Biopharma Announces Proposed Public Offering of Common Stock RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. |
|
| April 5, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| April 5, 2021 |
EX-1.1 2 ex-11underwriting.htm EX-1.1 9 METERS BIOPHARMA, INC. Common Stock, par value $0.0001 per share Underwriting Agreement March 30, 2021 Citigroup Global Markets Inc. William Blair & Company, L.L.C. Truist Securities, Inc. As representatives of the several Underwriters named in Schedule I hereto, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o William Blai |
|
| April 5, 2021 |
9 Meters Biopharma Announces Closing of Offering of Common Stock PRESS RELEASE 9 Meters Biopharma Announces Closing of Offering of Common Stock RALEIGH, NC / ACCESSWIRE / April 5, 2021 / 9 Meters Biopharma, Inc. |
|
| March 31, 2021 |
30,000,000 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration Number 333-249268 Prospectus supplement (To prospectus dated October 9, 2020) 30,000,000 Shares Common Stock We are offering 30,000,000 shares of our common stock. |
|
| March 30, 2021 |
Subject to completion, dated March 30, 2021 The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. |
|
| March 25, 2021 |
EX-99.1 2 ss195190ex9901.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. 3 to the Statement on this Schedule 13D, dated March 25, 2021 (the “Schedule 13D”), with respect to the Shares of 9 Meters Biopharma, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities an |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* 9 Meters Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45782F105 (CUSIP Number) OrbiMed Israel BioFund GP Limited Partnership OrbiMed Israel GP Ltd. Erez Chimovits 89 Medinat HaYehudim St. Build |
|
| March 23, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| March 23, 2021 |
A Champion in GI With A One Tract Mind Focused on Rare and Unmet Needs in Gastroenterology Short Bowel Syndrome R&D Day NM-002: Proprietary Long-Acting GLP-1 Agonist March 23, 2021 Forward Looking Statements 2 This presentation includes forward-looking statements based upon the Company's current expectations. |
|
| March 23, 2021 |
ex-991corporatepresentat A Champion in GI With A One Tract Mind Focused on Rare and Unmet Needs in Gastroenterology Corporate Presentation Forward Looking Statements 2 This press release includes forward-looking statements based upon the Company's current expectations. |
|
| March 22, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| March 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37797 9 METERS BIOPHA |
|
| March 22, 2021 |
PRESS RELEASE 9 Meters Biopharma Provides Business Update and Reports Financial Results for the Fourth Quarter and Full Year 2020 - FDA Type C meeting communications support plans to initiate Phase 2 in Q2 with NM-002 for short bowel syndrome (SBS) using Total Stool Output (TSO) as a primary efficacy outcome measure - - Announced positive topline data in December for NM-002, a proprietary long-act |
|
| March 22, 2021 |
List of Subsidiaries of Registrant. Exhibit 21.1 Subsidiaries of the Registrant Set forth below is a list of the significant subsidiaries of the Registrant. All of the subsidiaries listed below are wholly-owned subsidiaries of 9 Meters Biopharma, Inc. and are owned directly by 9 Meters Biopharma, Inc. Subsidiary Jurisdiction of Formation Naia Rare Diseases, LLC Delaware RDD Pharma Ltd. Israel |
|
| March 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| March 15, 2021 |
9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update Tuesday, March 23rd @ 11am Eastern Time. |
|
| March 10, 2021 |
9 Meters Biopharma, Inc. to Participate in the following Virtual March Investor Conferences - Oppenheimer 31st Annual Healthcare Conference - March 16th - 18th - Maxim Group 2021 Emerging Growth Virtual Conference - March 17th - 18th Raleigh, NC, March 10, 2021 – 9 Meters Biopharma, Inc. (Nasdaq: NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that ma |
|
| March 10, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizat |
|
| March 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organizati |
|
| March 9, 2021 |
EX-99.1 2 ex-991pressrelease3921.htm EX-99.1 9 Meters Biopharma, Inc. Appoints Michael Rice to Board of Directors 9 Meters Biopharma, Inc. Announces Chief Medical Officer’s Presentation at NIH’s Accelerating Progress in Celiac Disease Workshop RALEIGH, NC / ACCESSWIRE / March 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, a |
|
| March 1, 2021 |
9 Meters Biopharma, Inc. Appoints Michael Rice to Board of Directors 9 Meters Biopharma, Inc. Appoints Michael Rice to Board of Directors RALEIGH, NC / ACCESSWIRE / March 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Michael Rice to its board of directors. Mr. Rice is the president and co-founder of LifeSci Advisors, a life sciences investor relatio |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organi |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organi |
|
| February 10, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organi |
|
| February 10, 2021 |
9 Meters Biopharma, Inc. to Present at the 23rd Annual BIO CEO & Investor Conference 9 Meters Biopharma, Inc. to Present at the 23rd Annual BIO CEO & Investor Conference Raleigh, NC, February 10, 2021 – 9 Meters Biopharma, Inc. (Nasdaq: NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that its Chief Executive Officer, John Temperato, will present a corporate overview and participate in one-on-one investor meetings at the BIO CEO & Inve |
|
| February 3, 2021 |
EX-99.1 2 ex-991pressrelease2321.htm EX-99.1 9 Meters Biopharma, Inc. highlighted at upcoming Truist Securities’ CEO Strategic Vision Conference Call Series Raleigh, NC, February 3, 2021 – 9 Meters Biopharma, Inc. (Nasdaq: NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced its Executive Management team will participate in the “CEO Strategic Vision” Confe |
|
| February 3, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 3, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| February 1, 2021 |
9 Meters Biopharma, Inc. Announces Research & Development Day on Short Bowel Syndrome - SAVE THE DATE: Webinar Scheduled for March 23, 2021 @ 11 AM ET - Raleigh, NC, February 1, 2021 – 9 Meters Biopharma, Inc. (Nasdaq: NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that it will host a research and development day webinar on its clinical development p |
|
| February 1, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2021 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| January 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| December 28, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 9 Meters Biopharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 654405109 (CUSIP Number) December 15, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuan |
|
| December 21, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organi |
|
| December 21, 2020 |
EX-99.1 9 Meters Biopharma Announces Agreement with the European Biomedical Research Institute of Salerno (EBRIS) to Continue Evaluation of Larazotide for COVID-19 Respiratory Complications •Larazotide, a novel tight junction modulator, has shown positive effect in multiple lung models of acute respiratory distress, acute lung injury, and pulmonary fibrosis with potential effects in COVID-19 patie |
|
| December 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* 9 Meters Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45782F105 (CUSIP Number) OrbiMed Israel BioFund GP Limited Partnership OrbiMed Israel GP Ltd. Nissim Darvish 89 Medinat HaYehudim St. Build |
|
| December 16, 2020 |
EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. |
|
| December 15, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organi |
|
| December 15, 2020 |
9 Meters Biopharma, Inc. Announces Closing of Offering of Common Stock 9 Meters Biopharma, Inc. Announces Closing of Offering of Common Stock RALEIGH, NC / ACCESSWIRE / December 15, 2020 / 9 Meters Biopharma, Inc. (NASDAQ: NMTR) (the “Company”), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the closing of its previously announced underwritten public offering of 53,076,924 shares of its common stock, inclusive of the full over |
|
| December 15, 2020 |
9 Meters Biopharma, Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 9 Meters Biopharma, Inc. Announces Proposed Public Offering of Common Stock RALEIGH, NC / ACCESSWIRE / December 10, 2020 / 9 Meters Biopharma, Inc. (NASDAQ: NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today that it has commenced a proposed underwritten public offering of shares of its common stock. In connection with this offering, 9 Meters |
|
| December 15, 2020 |
9 Meters Biopharma, Inc. Prices Public Offering of Common Stock 9 Meters Biopharma, Inc. Prices Public Offering of Common Stock RALEIGH, NC / ACCESSWIRE / December 11, 2020 / 9 Meters Biopharma, Inc. (NASDAQ: NMTR) (the “Company”), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the pricing of an underwritten public offering of 46,153,847 shares of its common stock at a price to the public of $0.65 per share. In addition |
|
| December 15, 2020 |
9 METERS BIOPHARMA, INC. Common Stock, par value $0.0001 per share Underwriting Agreement December 11, 2020 William Blair & Company, L.L.C. Truist Securities, Inc. As representatives of the several Underwriters named in Schedule I hereto, c/o William Blair & Company, L.L.C. 150 North Riverside Plaza Chicago, Illinois 60606 c/o Truist Securities, Inc. 3333 Peachtree Road, 11th Floor Atlanta, Georgi |
|
| December 11, 2020 |
46,153,847 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration Number 333-249268 Prospectus supplement (To prospectus dated October 9, 2020) 46,153,847 Shares Common Stock We are offering 46,153,847 shares of our common stock. |
|
| December 10, 2020 |
NMTR / 9 Meters Biopharma, Inc. / Capital Point Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* 9 Meters Biopharma, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 654405109 (CUSIP Number) December 7, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| December 10, 2020 |
Subject to completion, dated December 10, 2020 The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| December 9, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 9, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| December 9, 2020 |
9 Meters Biopharma, Inc. Receives Orphan Drug Designation for NM-003, a Proprietary Long-Acting GLP-2, for Prevention of Acute Graft Versus Host Disease (aGvHD) -aGvHD among potential indications being considered for next stage of development -Candidate to move to IND-enabling studies in 2021 RALEIGH, NC / ACCESSWIRE / December 9, 2020 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rar |
|
| December 7, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 7, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| December 7, 2020 |
ex-992investorpresentati Positive Phase 1b/2a Topline Data in Short Bowel Syndrome -Rapid onset and sustained clinical effect following first dose in all 9 patients in total stool output (TSO) volume -Clinically relevant improvements in TSO volume and bowel movement frequency -Twice-monthly fixed-dosing regimen exhibited an excellent safety and tolerability profile -Plan to meet with FDA as soon as possible in the first quarter of 2021 to discuss next steps for clinical development of NM-002 Conference Call December 7, 2020 Forward Looking Statements This presentation includes forward-looking statements based upon the Company's current expectations. |
|
| December 7, 2020 |
9 Meters Biopharma, Inc. Announces Positive Topline Data for NM-002, a Proprietary Long-Acting GLP-1, in Phase 1b/2a Trial for Short Bowel Syndrome -Rapid onset and sustained clinical effect following first dose in all 9 patients in total stool output (TSO) volume -Clinically relevant improvements in TSO volume and bowel movement frequency -Twice-monthly fixed-dosing regimen exhibited an excellent |
|
| December 7, 2020 |
ex-991corporatepresentat A Champion in GI With A One Tract Mind Focused on Rare and Unmet Needs in Gastroenterology Forward Looking Statements This presentation includes forward-looking statements based upon the Company's current expectations. |
|
| December 7, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 7, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| November 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 20, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organi |
|
| November 27, 2020 |
Amendment to the 2012 Omnibus Incentive Plan, dated November 27, 2020. Exhibit 10.1 AMENDMENT TO THE 9 Meters Biopharma, Inc. 2012 OMNIBUS INCENTIVE PLAN, AS AMENDED WHEREAS, 9 Meters Biopharma, Inc. (the “Company”) maintains the 2012 Omnibus Incentive Plan (as amended from time to time, the “Plan”); WHEREAS, the Board of Directors of the Company (the “Board”) has the authority under Section 11.15(a) of the Plan to amend the Plan at any time; and WHEREAS, the Board a |
|
| November 16, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 16, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organi |
|
| November 16, 2020 |
Exhibit 99.1 9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model –NM-102, a novel next-generation microbiome modulator, shows positive effect in an aggressive immune checkpoint inhibitor failure melanoma model –IND-enabling planning underway RALEIGH, NC, November 16, 2020 – 9 Meters Biopharma, Inc. (NASDAQ: N |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37797 9 METE |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| November 9, 2020 |
Exhibit 99.1 9 Meters Biopharma, Inc. Provides Business Update and Announces Third Quarter 2020 Results Phase 1b/2a trial with a proprietary long-acting GLP-1 agonist in short bowel syndrome top-line data expected in Q4 Continued enrollment of Phase 3 trial with larazotide in celiac disease, interim analysis remains on target for 1H 2021 Raleigh, NC, November 9, 2020 - 9 Meters Biopharma, Inc. (Na |
|
| November 2, 2020 |
Exhibit 99.1 9 Meters Biopharma, Inc. to participate in the following November Virtual Investor Conferences - H.C. Wainwright Annual Israel Conference - November 12th - A.G.P. Virtual Healthcare Symposium 2020 - November 19th Raleigh, NC, November 2, 2020 - 9 Meters Biopharma, Inc. (Nasdaq: NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company announced today that managemen |
|
| November 2, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiz |
|
| October 9, 2020 |
As filed with the Securities and Exchange Commission on October 9, 2020 Registration Statement No. |
|
| October 9, 2020 |
9 METERS BIOPHARMA, INC. Up to $37,352,318 Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(5) Registration No. 333-249268 9 METERS BIOPHARMA, INC. Up to $37,352,318 Common Stock We have entered into a Sales Agreement, dated July 22, 2020 and amended on October 2, 2020, with Truist Securities, Inc. (formerly, SunTrust Robinson Humphrey, Inc.), or Truist, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectu |
|
| October 8, 2020 |
As filed with the Securities and Exchange Commission on October 8, 2020 Registration Statement No. |
|
| October 7, 2020 |
CORRESP 1 filename1.htm 9 METERS BIOPHARMA, INC. 8480 Honeycutt Road, Suite 120 Raleigh, North Carolina 27615 October 7, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ada Sarmento Division of Corporation Finance Office of Life Sciences Re: Acceleration Request 9 Meters Biopharma, Inc. Registratio |
|
| October 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiza |
|
| October 2, 2020 |
9 METERS BIOPHARMA, INC. and , as Trustee INDENTURE Dated as of , 20 TABLE OF CONTENTS Page ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 Definitions 1 1.2 Reserved 5 1.3 Incorporation by Reference of Trust Indenture Act 5 1.4 Rules of Construction 5 ARTICLE 2 - THE SECURITIES 6 2.1 Issuable in Series 6 2.2 Establishment of Terms of Series of Securities 6 2.3 Execution and Authentic |
|
| October 2, 2020 |
As filed with the Securities and Exchange Commission on October 2, 2020 Registration Statement No. |
|
| October 2, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 2, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiza |
|
| October 2, 2020 |
Exhibit 1.2 AMENDMENT NO. 1 TO SALES AGREEMENT October 2, 2020 Truist Securities, Inc. 3333 Peachtree Road, 11th Floor Atlanta, Georgia 30326 Ladies and Gentlemen: 9 Meters Biopharma, Inc., a Delaware corporation (the “Company”), and Truist Securities, Inc. (the “Agent”) are parties to that certain Sales Agreement, dated July 22, 2020, (the “Original Agreement”). All capitalized terms not defined |
|
| September 8, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organi |
|
| September 8, 2020 |
Exhibit 99.1 9 Meters Biopharma, Inc. to participate in September Investor Conferences - H.C. Wainwright: 22nd Annual Global Investment Conference - September 14 - 16 -Oppenheimer Fall Healthcare Life Sciences & MedTech Summit - September 21 - 23 Raleigh, NC, September 8, 2020 - 9 Meters Biopharma, Inc. (Nasdaq: NMTR), today announced that management will participate in the following conferences i |
|
| September 3, 2020 |
NMTR / 9 Meters Biopharma, Inc. / Capital Point Ltd. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* 9 Meters Biopharma, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 654405109 (CUSIP Number) April 30, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| August 31, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 31, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiza |
|
| August 31, 2020 |
9 Meters Biopharma, Inc. Announces Formation of Scientific Advisory Board Exhibit 99.1 9 Meters Biopharma, Inc. Announces Formation of Scientific Advisory Board Raleigh, NC, August 31, 2020 - 9 Meters Biopharma, Inc. (Nasdaq: NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the formation of its scientific advisory board (SAB). The SAB comprises an esteemed group of six experts in the gastroenterology field with sub-specialti |
|
| August 26, 2020 |
Wyrick Robbins Yates & Ponton LLP ATTORNEYS AT LAW 4101 Lake Boone Trail, Suite 300, Raleigh, NC 27607 PO Drawer 17803, Raleigh, NC 27619 P: 919. |
|
| August 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 18, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiza |
|
| August 13, 2020 |
Exhibit 10.7 CONFIDENTIAL PORTIONS OF THIS LICENSE AMENDMENT HAVE BEEN OMITTED PURSUANT TO REGULATION S-K ITEM 601(b)(10)(iv) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (i) IS NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO 9 METERS BIOPHARMA INC. IF PUBLICLY DISCLOSED. THE REDACTED TERMS HAVE BEEN MARKED |
|
| August 13, 2020 |
Side Letter, dated May 1, 2020, between Amunix Pharmaceuticals, Inc. and Naia Rare Diseases, Inc. EX-10.8 3 ex-108sideletter.htm EXHIBIT 10.8 Exhibit 10.8 CONFIDENTIAL PORTIONS OF THIS SIDE LETTER HAVE BEEN OMITTED PURSUANT TO REGULATION S-K ITEM 601(b)(10)(iv) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (i) IS NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO 9 METERS BIOPHARMA, INC. IF PUBLICLY DISCLOSE |
|
| August 13, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiza |
|
| August 13, 2020 |
As filed with the Securities and Exchange Commission on August 13, 2020 Registration No. |
|
| August 13, 2020 |
As filed with the Securities and Exchange Commission on August 13, 2020 Registration No. |
|
| August 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37797 9 METERS BI |
|
| August 13, 2020 |
Exhibit 10.10 CONFIDENTIAL PORTIONS OF THIS AMENDED AND RESTATED LICENSE AMENDMENT HAVE BEEN OMITTED PURSUANT TO REGULATION S-K ITEM 601(b)(10)(iv) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (i) IS NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO 9 METERS BIOPHARMA, INC. IF PUBLICLY DISCLOSED. THE REDACTED |
|
| August 13, 2020 |
Exhibit 10.9 CONFIDENTIAL PORTIONS OF THIS AMENDED AND RESTATED LICENSE AMENDMENT HAVE BEEN OMITTED PURSUANT TO REGULATION S-K ITEM 601(b)(10)(iv) OF THE SECURITIES ACT OF 1933, AS AMENDED. CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (i) IS NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO 9 METERS BIOPHARMA, INC. IF PUBLICLY DISCLOSED. THE REDACTED T |
|
| August 13, 2020 |
Exhibit 99.1 9 Meters Biopharma, Inc. highlighted at upcoming Truist Securities’ Catalyst Conference Call Series: “Prepping ahead of data” - Conference Call Scheduled for August 18, 2020 - Raleigh, NC, August 13, 2020 - 9 Meters Biopharma, Inc. (Nasdaq: NMTR), today announced that the Executive Management team will participate in the “Prepping ahead of Data” Conference Call Series hosted by hosted |
|
| August 13, 2020 |
Form of RDD Pharma, Ltd. Notice of Option Grant. Exhibit 10.11 RDD PHARMA LTD (the "Company") NOTICE OF OPTION GRANT This Notice of Grant hereby sets forth the terms and conditions to which the Options to purchase Preferred Shares of the Company, par value NIS 1.00 each (the “Shares” and the “Options”, respectively) granted to the undersigned (the "Grantee") are subject: Name of the Grantee: [] Address: [] Date of Grant: January 23, 2020 Designa |
|
| August 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2020 9 Meters Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37797 27-3948465 (State or other jurisdiction of incorporation or organiza |
|
| August 12, 2020 |
Exhibit 99.1 9 Meters Biopharma, Inc. Provides Business Update and Announces Second Quarter 2020 Results -Initiates Phase 1b/2a clinical trial with a proprietary long-acting GLP-1 agonist, in short bowel syndrome; first patients dosed in July and top-line data expected by Q1 2021 - - Amended definition of primary endpoint for Phase 3 trial with larazotide in celiac disease, allowing reduction in p |
|
| August 4, 2020 |
Exhibit 99.1 9 Meters Biopharma, Inc. to participate in August Investor Conferences -William Blair Biotech Focus Conference- August 4th- 6th -BTIG Virtual Biotechnology Conference- August 10th & 11th Raleigh, NC, August 4, 2020 - 9 Meters Biopharma, Inc. (Nasdaq: NMTR), today announced that management will participate in the following conferences in the month of August and invites investors to par |
